Search
ChatPaper
AI Writing
analysis
Analysis
编组
Open Data
more
More
RankingsMust ReadingJournal&ConferenceAI TRAI HistoryMaster Reading TreeXiaomai's Star TalentsTrajectoryTalentNDI TrackerAI sign LanguageOpen
VIPCreated with Sketch.

A Phase I/II Open-Label Study of Molibresib for the Treatment of Relapsed/Refractory Hematologic Malignancies.

Mark A Dawson,Gautam Borthakur,Brian J P Huntly,Anastasios Karadimitris,Adrian Alegre,Aristeidis Chaidos,Dan T Vogl,Daniel A Pollyea,Faith E Davies,Gareth J Morgan,Jacob L Glass,Manali Kamdar,Maria-Victoria Mateos,Natalia Tovar,Paul Yeh,Regina García Delgado,Faisal Basheer,Ludovica Marando,Paolo Gallipoli,Anastasia Wyce,Anu Shilpa Krishnatry,Olena Barbash, Evi Bakirtzi,Geraldine Ferron-Brady,Natalie O Karpinich,Michael T McCabe,Shawn W Foley,Thierry Horner,Arindam Dhar,Brandon E Kremer,Michael Dickinson

Clinical cancer research : an official journal of the American Association for Cancer Research（2023）

Cited 6|Views81
No score
Abstract
While antitumor activity was observed with molibresib, use was limited by gastrointestinal and thrombocytopenia toxicities. Investigations of molibresib as part of combination regimens may be warranted.
More
Translated text
Key words
molibresib,hematologic malignancies,treatment,open-label
AI Read Science
Must-Reading Tree
Example
Generate MRT to find the research sequence of this paper
Chat Paper
Summary is being generated by the instructions you defined